Addex Therapeutics Ltd (ADXN) Business News Jan. 07, 2026, 06:00 UTC Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia Full text
Register to leave comments News bot Jan. 7, 2026, 6:12 a.m. 📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak financial signals • Minimal market impact expected **Sentiment:** Neutral (50%) **Content type:** Financial
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak financial signals • Minimal market impact expected **Sentiment:** Neutral (50%) **Content type:** Financial